Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 1000-1011

  Hagberg, Niklas ^a   Theorell, Jakob ^b   Hjorton, Karin ^a   Spee, Pieter ^c   Eloranta, Maija Leena ^a   Bryceson, Yenan T ^b,d   Rönnblom, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD94 ANTIBODY; HLA E ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2C; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY D;

ADOLESCENT; ADULT; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DEGRANULATION; DEGRANULATION ASSAY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; K562 CELL LINE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; BLOOD; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

AUTOANTIBODIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D;

EID: 84925786908     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38999     Document Type: Article

References (44)

1. Tsokos GC,. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-21.
2. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L,. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861-72.
3. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3: 73ra19.
4. Wener MH, Uwatoko S, Mannik M,. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum 1989; 32: 544-51.
5. Tzioufas AG, Kokori SI, Petrovas CI, Moutsopoulos HM,. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum 1997; 40: 2212-6.
6. Mimura T, Fernsten P, Jarjour W, Winfield JB,. Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus. J Exp Med 1990; 172: 653-6.
7. Lenert P, Lenert G, Senecal JL,. CD4-reactive antibodies in systemic lupus erythematosus. Hum Immunol 1996; 49: 38-48.
8. Boros P, Muryoi T, Spiera H, Bona C, Unkeless JC,. Autoantibodies directed against different classes of FcγR are found in sera of autoimmune patients. J Immunol 1993; 150: 2018-24.
9. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115: 996-1005.
10. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B,. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189-93.
11. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C,. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343-51.
12. Waggoner SN, Cornberg M, Selin LK, Welsh RM,. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2011; 481: 394-8.
13. Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996; 23: 171-7.
14. Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P,. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 1993; 2: 227-31.
15. Hoffman T,. Natural killer function in systemic lupus erythematosus. Arthritis Rheum 1980; 23: 30-5.
16. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1753-63.
17. Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum 2011; 63: 1698-706.
18. Hagberg N, Berggren O, Leonard D, Weber G, Bryceson YT, Alm GV, et al. IFN-α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1β and LFA-1. J Immunol 2011; 186: 5085-94.
19. Rook AH, Tsokos GC, Quinnan GV Jr, Balow JE, Ramsey KM, Stocks N, et al. Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus. Clin Immunol Immunopathol 1982; 24: 179-85.
20. Ytterberg SR, Huard TK, Schnitzer TJ,. Effects of serum from patients with systemic lupus erythematosus on leukocyte cytotoxicity: modulation of NK activity and ADCC. J Rheumatol 1983; 10: 906-12.
21. Hagberg N, Theorell J, Eloranta ML, Pascal V, Bryceson YT, Ronnblom L,. Anti-NKG2A autoantibodies in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 2013; 52: 1818-23.
22. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795-9.
23. Kaiser BK, Pizarro JC, Kerns J, Strong RK,. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci U S A 2008; 105: 6696-701.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
25. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
26. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
27. Gladman DD, Ibanez D, Urowitz MB,. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
28. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
29. Churg J, Bernstein J, Glassock RJ,. Lupus nephritis. In: Renal disease: classification and atlas of glomerular diseases. 2nd ed. New York: Igaku-Shoin; 1995. p. 151-5.
30. Lanier LL, Corliss B, Wu J, Phillips JH,. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998; 8: 693-701.
31. Wu J, Song YL, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-2.
32. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L,. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54: 1917-27.
33. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK,. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005; 174: 2878-84.
34. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M,. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004; 104: 3664-71.
35. Goldblatt F, O'Neill SG,. Clinical aspects of autoimmune rheumatic diseases. Lancet 2013; 382: 797-808.
36. Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpfennig KW, Cantor H,. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007; 26: 593-604.
37. 2. Proc Natl Acad Sci U S A 2010; 107: 2562-7.
38. Leavenworth JW, Wang X, Wenander CS, Spee P, Cantor H,. Mobilization of natural killer cells inhibits development of collagen-induced arthritis. Proc Natl Acad Sci U S A 2011; 108: 14584-9.
39. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25: 331-42.
40. Joncker NT, Shifrin N, Delebecque F, Raulet DH,. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 2010; 207: 2065-72.
41. Elliott JM, Wahle JA, Yokoyama WM,. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 2010; 207: 2073-9.
42. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G,. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398-400.
43. Ward MM, Pajevic S, Dreyfuss J, Malley JD,. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum 2006; 55: 74-80.
44. Matsui T, Otsuka M, Maenaka K, Furukawa H, Yabe T, Yamamoto K, et al. Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases. Arthritis Rheum 2001; 44: 384-8.